Compare Stocks → Biden’s $374B Giveaway Into This Sector (From DTI) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ARCTNASDAQ:AVEONASDAQ:CALANASDAQ:CERCNASDAQ:CNCE Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARCTArcturus Therapeutics$26.32-4.8%$35.42$17.52▼$43.81$708.53M2.6457,498 shs607,514 shsAVEOAVEO Pharmaceuticals$15.00$14.97$3.06▼$15.00$521.45M1601,442 shs247,800 shsCALACalithera Biosciences$0.03-28.5%$0.02$0.01▼$0.50$122K-0.171,607 shs1,075 shsCERCCerecor$12.01-11.8%$2.60$1.98▼$4.50$1.15B1.441.27 million shs104,653 shsCNCEConcert Pharmaceuticals$8.37$8.37$2.66▼$8.55$401.26M0.522.97 million shsN/A10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARCTArcturus Therapeutics-4.78%-19.11%-22.04%-19.68%-5.90%AVEOAVEO Pharmaceuticals0.00%0.00%0.00%0.00%0.00%CALACalithera Biosciences-37.38%+25.25%-0.20%-19.84%-51.83%CERCCerecor-24.65%-23.75%+176.09%+185.27%+308.67%CNCEConcert Pharmaceuticals0.00%0.00%0.00%0.00%0.00%New crypto project uncovers 2,050% in 65 days (Ad)During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.Just click here to sign up and be among the first to get it.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARCTArcturus Therapeutics1.8423 of 5 stars3.50.00.00.02.63.30.6AVEOAVEO PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACALACalithera BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ACERCCerecorN/AN/AN/AN/AN/AN/AN/AN/ACNCEConcert PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARCTArcturus Therapeutics3.00Buy$61.33133.03% UpsideAVEOAVEO PharmaceuticalsN/AN/AN/AN/ACALACalithera BiosciencesN/AN/AN/AN/ACERCCerecorN/AN/AN/AN/ACNCEConcert PharmaceuticalsN/AN/AN/AN/ACurrent Analyst RatingsLatest CNCE, CALA, AVEO, ARCT, and CERC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/20/2024ARCTArcturus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.003/8/2024ARCTArcturus TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform2/8/2024ARCTArcturus TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$40.00 ➝ $48.00(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARCTArcturus Therapeutics$169.93M4.17N/AN/A$10.42 per share2.53AVEOAVEO Pharmaceuticals$42.29M12.33N/AN/A$1.33 per share11.28CALACalithera Biosciences$9.75M0.01N/AN/A($0.40) per share-0.06CERCCerecor$6.70M172.10N/AN/A$0.22 per share54.59CNCEConcert Pharmaceuticals$32.58M12.32N/AN/A$3.24 per share2.58Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARCTArcturus Therapeutics-$29.73M-$1.04N/A5.16N/A-15.65%-18.22%-11.95%5/14/2024 (Estimated)AVEOAVEO Pharmaceuticals-$53.34M-$0.84N/A28.85N/A-30.79%-81.66%-28.83%N/ACALACalithera Biosciences-$39.65MN/A0.00∞N/AN/AN/AN/AN/ACERCCerecor-$63.50M-$0.57N/AN/AN/A-1,194.82%-261.82%-133.96%N/ACNCEConcert Pharmaceuticals-$80.05M-$3.21N/AN/AN/AN/A-109.43%-76.65%N/ALatest CNCE, CALA, AVEO, ARCT, and CERC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/7/2024Q4 2023ARCTArcturus Therapeutics-$1.69-$0.32+$1.37-$0.32$64.14 million$33.99 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARCTArcturus TherapeuticsN/AN/AN/AN/AN/AAVEOAVEO PharmaceuticalsN/AN/AN/AN/AN/ACALACalithera BiosciencesN/AN/AN/AN/AN/ACERCCerecorN/AN/AN/AN/AN/ACNCEConcert PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARCTArcturus TherapeuticsN/A4.724.72AVEOAVEO Pharmaceuticals0.942.372.35CALACalithera BiosciencesN/AN/AN/ACERCCerecor0.792.192.18CNCEConcert PharmaceuticalsN/A9.039.03OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARCTArcturus Therapeutics94.54%AVEOAVEO Pharmaceuticals49.95%CALACalithera BiosciencesN/ACERCCerecor62.84%CNCEConcert Pharmaceuticals70.63%Insider OwnershipCompanyInsider OwnershipARCTArcturus Therapeutics13.80%AVEOAVEO Pharmaceuticals3.29%CALACalithera Biosciences6.60%CERCCerecor45.70%CNCEConcert Pharmaceuticals11.33%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableARCTArcturus Therapeutics18026.92 million23.20 millionOptionableAVEOAVEO Pharmaceuticals11434.76 million33.62 millionOptionableCALACalithera Biosciences84.87 million4.55 millionNot OptionableCERCCerecor3196.01 millionN/ANot OptionableCNCEConcert Pharmaceuticals6447.94 million42.51 millionOptionableCNCE, CALA, AVEO, ARCT, and CERC HeadlinesSourceHeadlineThe Best Bag to Bring to a Concert Is Actually a Running Beltnytimes.com - April 7 at 3:45 PMTeresa Giudice and Her Lookalike Daughters Glam Up for Nicki Minaj Concert: ‘New Jersey Takes Gag City’au.news.yahoo.com - April 1 at 10:28 PMChords against cancerhub.jhu.edu - March 31 at 12:01 AMVideo: Pharma boss apologises after pill linked to five deaths and over 100 hospitalisationsmsn.com - March 30 at 8:59 AMThe Effects Of Dobbs On Cancer Carehealthaffairs.org - March 30 at 8:59 AMWalt Disney Concert Halltimeout.com - November 24 at 12:00 AMWhen she was just a teen. 11 highlights from a Taylor Swift concert in rural Florida in 2007news-press.com - November 8 at 10:08 AMNFL pushed networks to air Taylor Swift concert film promos — for freenypost.com - October 28 at 11:46 PMAll the best concerts and gigs coming up in Dubaitimeoutdubai.com - October 23 at 7:11 PMTaylor Swift’s ‘The Eras Tour’ Extends Its Lead as the Top Music Concert Film of All Time: Here’s the Top 10billboard.com - October 23 at 7:11 PMConcerts Help Drive Demand for Travel in 2023nerdwallet.com - October 20 at 8:56 AMBeyoncé 'Renaissance' Movie Tickets and How To See Concert Film in Theatersmsn.com - October 2 at 2:21 PMNewJeans, ATEEZ and more to perform at ‘Immortal Songs’ live concert in New Yorknme.com - September 29 at 3:33 PMConcerts at the Etihad Stadiummancity.com - September 23 at 12:44 PMAll the concerts canceled by extreme heat in Phoenix this summer, from 50 Cent to Disturbedazcentral.com - September 17 at 12:47 AMTaylor Swift 'overjoyed' to release Eras Tour concert movie: How to watchusatoday.com - September 15 at 7:06 PMBruce Springsteen forced to postpone Philadelphia concerts with E Street Band due to illnessusatoday.com - September 12 at 10:17 PMFall guide to fun in Indianapolis: Concerts, free shows and date ideasindystar.com - September 11 at 11:04 PMChasing Lilly, Concert eyes 2023 filing for its JAK drug for alopeciapharmaphorum.com - August 18 at 2:03 PMMiranda Lambert scolds fans for taking selfies during her concert: 'I don't like it'usatoday.com - August 7 at 7:37 AMThe worst people at concerts, from self-involved selfie takers to nonstop filmersusatoday.com - August 6 at 4:42 AMHighlights from King Charles III Coronation concertbbc.co.uk - July 25 at 2:38 AMChelsea Handler Bartends During Bruce Springsteen's London Concert: 'What a Ducking Show'people.com - July 23 at 7:00 PMFan throws bag of ashes at Pink during tour concertusatoday.com - July 17 at 8:19 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsArcturus TherapeuticsNASDAQ:ARCTArcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.AVEO PharmaceuticalsNASDAQ:AVEOAVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.Calithera BiosciencesNASDAQ:CALACalithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.CerecorNASDAQ:CERCCerecor, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.Concert PharmaceuticalsNASDAQ:CNCEConcert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.